Moral implications of laboratory-based experimental trauma analysis are usually not properly studied. Feminine rape survivors (N = 62) and controls (N = 79) listened to an audio recording of a sexual assault and accomplished psychological well being measures and the Reactions to Analysis Participation Questionnaire-Revised within the first session and once more a number of weeks later.
Within the first session, psychological well being signs had been related to stronger emotional reactions and private advantages from participation. Rape survivors additionally reported stronger emotional reactions than controls, but additionally extra private advantages, extra satisfaction, and fewer perceived drawbacks from participation. A number of weeks later, each teams reported diminished posttraumatic stress dysfunction signs and rape survivors’ stories of stronger emotional reactions and better satisfaction with their participation remained vital. Profit-cost ratios point out optimistic responses to participation throughout teams and time. Findings recommend vital advantages to laboratory trauma analysis for contributors.
Worldwide Rickettsia Illness Surveillance: An Instance of Cooperative Analysis to Enhance Laboratory Functionality and Capability for Threat Evaluation of Rickettsial Outbreaks Worldwide
Cooperative analysis that addresses infectious illness surveillance and outbreak investigations depends closely on availability and efficient use of acceptable diagnostic instruments, together with serological and molecular assays, as exemplified by the present COVID-19 pandemic. On this paper, we stress the significance of utilizing these assays to assist collaborative epidemiological research to evaluate danger of rickettsial illness outbreaks amongst worldwide associate international locations.
Workforce improvement, mentorship, and coaching are essential elements in constructing laboratory functionality and capability to evaluate danger of and mitigate rising illness outbreaks. Worldwide partnerships that fund cooperative analysis by means of mentoring and on-the-job coaching are profitable examples for enhancing infectious illness surveillance. Cooperative analysis research between the Naval Medical Analysis Heart’s Rickettsial Ailments Analysis Program (RDRP) and 17 institutes from 9 international locations amongst 5 continents had been performed to deal with the presence of and the danger for endemic rickettsial illnesses.
To determine serological and molecular assays within the collaborative institutes, preliminary coaching and continued materials, and technical assist had been supplied by RDRP. The laboratory strategies used within the analysis research to detect and establish the rickettsial infections included (1) group-specific IgM and IgG serological assays and (2) molecular assays.
Twenty-six cooperative analysis initiatives carried out between 2008 and 2020 enhanced the potential and capability of 17 analysis institutes to estimate danger of rickettsial illnesses. These worldwide collaborative research have led to the popularity and/or affirmation of rickettsial illnesses inside every of the associate international locations. As well as, with the identification of particular pathogen and non-pathogen Rickettsia species, a extra correct danger evaluation may very well be made in surveillance research utilizing environmental samples.
The discoveries from these initiatives bolstered worldwide cooperation benefiting not solely the associate international locations but additionally the scientific group at massive by means of shows (n = 40) at worldwide scientific conferences and peer-reviewed publications (n = 18). The cooperative analysis research performed in a number of worldwide institutes led to the incorporation of latest SOPs and trainings for laboratory procedures; biosafety, biosurety, and biosecurity strategies; efficiency of rickettsia-specific assays; and the identification of identified and unknown rickettsial brokers by means of the introduction of latest serologic and molecular assays that complemented conventional microbiology strategies.
Laboratory Preparation of Monochloramine for Environmental Analysis: A Comparability of 4 Generally Used Protocols
Monochloramine (MCA) is commonly used as a secondary disinfectant in ingesting water distribution techniques (DWDS) for controlling the regrowth of microorganisms. Laboratory experiments to check the efficacy of MCA and formation of disinfection byproducts in DWDS all require the preparation of MCA. Completely different protocols for the preparation of MCA have been used within the literature.
On this research, we in contrast 4 printed protocols which can be ceaselessly used to arrange MCA within the environmental analysis group. Our outcomes confirmed that the selection of protocol might end in substantial variations in decay kinetics and disinfection efficacy of the ready MCA. The discrepancies spotlight a direct want for the standardization of MCA preparation protocols for laboratory-scale ingesting water analysis.
Human Laboratory Fashions of Hashish Use: Functions for Medical and Translational Psychiatry Analysis
Hashish is more and more utilized by people with psychological well being diagnoses and sometimes presupposed to deal with anxiousness and varied different psychiatric signs. But assist for utilizing hashish as a psychiatric remedy is at present restricted by a scarcity of proof from rigorous placebo-controlled research. Whereas regulatory hurdles and different boundaries make scientific trials of hashish difficult to conduct, dependancy researchers have a long time of expertise finding out hashish use in human laboratory fashions. These embrace strategies to manage hashish administration, to delineate scientific and mechanistic elements of hashish use, and to guage potential remedy functions for hashish and its constituents.
On this paper, we overview these human laboratory procedures and describe how every may be utilized to check hashish use in sufferers with psychiatric issues. As a result of anxiousness issues are among the many most typical psychiatric sicknesses affecting American adults, and anxiousness reduction can also be essentially the most commonly-reported purpose for medicinal hashish use, we focus notably on making use of human laboratory fashions to check hashish results in people with anxiousness and associated issues. Lastly, we focus on how these strategies may be built-in to check hashish results in different psychiatric situations and information future analysis on this space.
The intestine microbiome of laboratory mice: concerns and finest practices for translational analysis
Simply because the intestine microbiota (GM) is now acknowledged as an integral mediator of environmental influences on human physiology, susceptibility to illness, and response to pharmacological intervention, so too does the GM of laboratory mice have an effect on the phenotype of analysis utilizing mouse fashions. A number of experimental elements have been proven to have an effect on the composition of the GM in analysis mice, in addition to the mannequin phenotype, suggesting that the GM represents a significant element in experimental reproducibility.
 Progesterone Receptor Antibody |
|||
| ABF6107 | Lifescience Market | 100 ug | EUR 438 |
 Progesterone Receptor antibody |
|||
| 70R-50201 | Fitzgerald | 100 ul | EUR 287 |
|
Description: Purified Polyclonal Progesterone Receptor antibody |
|||
Progesterone Receptor antibody |
|||
| 70R-37509 | Fitzgerald | 100 ug | EUR 273 |
|
Description: Rabbit Polyclonal Progesterone Receptor antibody |
|||
Progesterone Receptor antibody |
|||
| 70R-32466 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit polyclonal Progesterone Receptor antibody |
|||
Progesterone Receptor antibody |
|||
| 70R-32467 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit polyclonal Progesterone Receptor antibody |
|||
Progesterone Receptor Antibody |
|||
| 49338-100ul | SAB | 100ul | EUR 333 |
Progesterone Receptor Antibody |
|||
| 49338-50ul | SAB | 50ul | EUR 239 |
 Progesterone receptor antibody |
|||
| 23053-100ul | SAB | 100ul | EUR 390 |
Progesterone Receptor antibody |
|||
| 20R-1934 | Fitzgerald | 50 ug | EUR 281 |
|
Description: Rabbit polyclonal Progesterone Receptor antibody |
|||
Progesterone Receptor antibody |
|||
| 20R-2250 | Fitzgerald | 50 ug | EUR 281 |
|
Description: Rabbit polyclonal Progesterone Receptor antibody |
|||
Progesterone receptor antibody |
|||
| 70R-13656 | Fitzgerald | 100 ul | EUR 457 |
|
Description: Affinity purified Rabbit polyclonal Progesterone receptor antibody |
|||
 Antibody) Progesterone Receptor(PR484) Antibody |
|||
| BNC610484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC610484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF660R conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) Progesterone Receptor(PR500) Antibody |
|||
| BNC610500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC610500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF660R conjugate, Concentration: 0.1mg/mL |
|||
 Antibody) Progesterone Receptor(PR501) Antibody |
|||
| BNC610501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC610501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC680484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC680484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC680500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC680500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC680501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC680501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC400484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC400484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC400500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC400500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC400501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC400501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC430484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC430484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC430500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC430500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC430501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC430501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC470484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC470484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC470500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC470500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC470501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC470501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC550484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC550484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC550500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC550500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC550501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC550501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC040484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC040484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC040500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC040500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC040501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC040501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC050484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC050484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC050500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC050500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC050501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC050501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNUM0484-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Progesterone Receptor(PR484), 1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNUM0500-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Progesterone Receptor(PR500), 1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNUM0501-50 | Biotium | 50uL | EUR 395 |
|
Description: Primary antibody against Progesterone Receptor(PR501), 1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC700484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC700484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC700500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC700500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC700501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC700501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC940484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC940484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC940500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC940500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC940501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC940501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCH0484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCH0484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCH0500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCH0500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCH0501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCH0501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC800484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC800484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC800500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC800500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC800501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC800501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC810484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC810484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC810500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC810500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC810501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC810501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCP0484-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR484), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCP0500-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR500), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCP0501-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR501), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCR0484-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR484), RPE conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCR0500-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR500), RPE conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCR0501-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR501), RPE conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCA0484-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR484), APC conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCA0500-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR500), APC conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCA0501-250 | Biotium | 250uL | EUR 383 |
|
Description: Primary antibody against Progesterone Receptor(PR501), APC conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCAP0484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCAP0484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCAP0500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCAP0500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCAP0501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCAP0501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCB0484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNCB0484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCB0500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNCB0500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCB0501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNCB0501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC880484-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNC880484-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR484), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC880500-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNC880500-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR500), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC880501-100 | Biotium | 100uL | EUR 199 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNC880501-500 | Biotium | 500uL | EUR 544 |
|
Description: Primary antibody against Progesterone Receptor(PR501), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNUB0484-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Concentration: 0.2mg/mL |
|||
Progesterone Receptor(PR484) Antibody |
|||
| BNUB0484-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Progesterone Receptor(PR484), Concentration: 0.2mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNUB0500-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Concentration: 0.2mg/mL |
|||
Progesterone Receptor(PR500) Antibody |
|||
| BNUB0500-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Progesterone Receptor(PR500), Concentration: 0.2mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNUB0501-100 | Biotium | 100uL | EUR 209 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Concentration: 0.2mg/mL |
|||
Progesterone Receptor(PR501) Antibody |
|||
| BNUB0501-500 | Biotium | 500uL | EUR 458 |
|
Description: Primary antibody against Progesterone Receptor(PR501), Concentration: 0.2mg/mL |
|||
 Progesterone Receptor Monoclonal Antibody |
|||
| EM1158-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Mouse Monoclonal antibody against Progesterone Receptor from Human/ Rat/ Mouse. This antibody is tested and validated for IHC, IF |
|||
Furthermore, a number of current research recommend that manipulation of the GM of laboratory mice can considerably enhance the predictive energy or translatability of information generated in mouse fashions to the human situations beneath investigation. This overview supplies readers with info associated to those varied elements and practices, and suggestions concerning strategies by which points with poor reproducibility or translatability may be reworked into discoveries.